- Home
- LSPD vs AUPH Comparison
LSPD vs AUPH Comparison
Compare LSPD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | AUPH |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LSPD | AUPH |
|---|---|---|
| Price | $9.42 | $13.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | $13.40 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.2M | 721.0K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $15.43 | $21.76 |
| Revenue Next Year | $11.26 | $16.45 |
| P/E Ratio | ★ N/A | $6.97 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $7.34 | $6.83 |
| 52 Week High | $14.34 | $16.54 |
Technical Indicators
Market Signals| Indicator | LSPD | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 37.48 |
| Support Level | $8.41 | $11.05 |
| Resistance Level | $12.55 | $16.28 |
| Average True Range (ATR) | 0.38 | 0.44 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 82.73 | 27.01 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.